Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ambrosia artemisiifolia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Ambrosia artemisiifolia. Displaying page 1 of 1.
    EudraCT Number: 2011-004522-10 Sponsor Protocol Number: Lais-Amb-11 Start Date*: 2012-05-06
    Sponsor Name:LOFARMA
    Full Title: Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia
    Medical condition: rhinoconjunctivitis allergic to ragweed pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10054928 Allergy to plants PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003864-20 Sponsor Protocol Number: P05234 Start Date*: 2009-04-14
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH 39641) in ...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004341-27 Sponsor Protocol Number: MK-3641-008 Start Date*: 2016-01-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a Histo...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) HR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005713-35 Sponsor Protocol Number: RPE 04 Start Date*: 2007-03-20
    Sponsor Name:Curalogic A/S
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL MICROENCAPSULATED RAGWEED POLLEN EXTRACT ADMINISTERED PRIOR TO AND DURING THE RAGWEED ...
    Medical condition: Treatment of seasonal allergic rhinitis to ragweed pollen.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004538-18 Sponsor Protocol Number: RPE 07 Start Date*: 2007-12-19
    Sponsor Name:Curalogic A/S
    Full Title: A randomized doble-blind placebo-controlled study to assess the safety in a one-year of orally administered microencapsulated ragweed pollen extract
    Medical condition: Patients with ragweed pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001682-41 Sponsor Protocol Number: HLS03/2011 Start Date*: 2011-05-09
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Comparison of the efficacy and the safety of different schedules of administration of sub-lingual immunotherapy in patients with ragweed pollinosis: a phase III randomized and controlled clinical s...
    Medical condition: Subjects who are allergic to Ragweed.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 04:22:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA